{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:48:24Z","timestamp":1787028504462,"version":"build-2736575974"},"reference-count":36,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health (Ricerca Corrente)","award":["668353"],"award-info":[{"award-number":["668353"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Adequate imatinib plasma levels are necessary to guarantee an efficacious and safe treatment in gastrointestinal stromal tumor (GIST) and chronic myeloid leukemia (CML) patients. Imatinib is a substrate of the drug transporters ATP-binding cassette subfamily B member 1 (ABCB1) and ATP-binding cassette subfamily G member 2 (ABCG2) that can affect its plasma concentration. In the present study, the association between three genetic polymorphisms in ABCB1 (rs1045642, rs2032582, rs1128503) and one in ABCG2 (rs2231142) and the imatinib plasma trough concentration (Ctrough) was investigated in 33 GIST patients enrolled in a prospective clinical trial. The results of the study were meta-analyzed with those of other seven studies (including a total of 649 patients) selected from the literature through a systematic review process. The ABCG2 c.421C&gt;A genotype demonstrated, in our cohort of patients, a borderline association with imatinib plasma trough levels that became significant in the meta-analysis. Specifically, homozygous carriers of the ABCG2 c.421 A allele showed higher imatinib plasma Ctrough with respect to the CC\/CA carriers (Ctrough, 1463.2 ng\/mL AA, vs. 1196.6 ng\/mL CC + AC, p = 0.04) in 293 patients eligible for the evaluation of this polymorphism in the meta-analysis. The results remained significant under the additive model. No significant association could be described between ABCB1 polymorphisms and imatinib Ctrough, neither in our cohort nor in the meta-analysis. In conclusion, our results and the available literature studies sustain an association between ABCG2 c.421C&gt;A and imatinib plasma Ctrough in GIST and CML patients.<\/jats:p>","DOI":"10.3390\/ijms24043303","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T03:01:45Z","timestamp":1675825305000},"page":"3303","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4205-2741","authenticated-orcid":false,"given":"Chiara","family":"Dalle Fratte","sequence":"first","affiliation":[{"name":"Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9381-1520","authenticated-orcid":false,"given":"Jerry","family":"Polesel","sequence":"additional","affiliation":[{"name":"Unit of Cancer Epidemiology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Gagno","sequence":"additional","affiliation":[{"name":"Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Posocco","sequence":"additional","affiliation":[{"name":"Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4948-8767","authenticated-orcid":false,"given":"Elena","family":"De Mattia","sequence":"additional","affiliation":[{"name":"Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4219-6182","authenticated-orcid":false,"given":"Rossana","family":"Roncato","sequence":"additional","affiliation":[{"name":"Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6601-5780","authenticated-orcid":false,"given":"Marco","family":"Orleni","sequence":"additional","affiliation":[{"name":"Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy"},{"name":"Doctoral School in Pharmacological Sciences, University of Padua, 35131 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0573-4938","authenticated-orcid":false,"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Unit of Medical Oncology and Cancer Prevention, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy"},{"name":"Department of Medicine, University of Udine, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5052-3502","authenticated-orcid":false,"given":"Michela","family":"Guardascione","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Unit of Medical Oncology and Cancer Prevention, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1930-0308","authenticated-orcid":false,"given":"Angela","family":"Buonadonna","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Unit of Medical Oncology and Cancer Prevention, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5323-4762","authenticated-orcid":false,"given":"Giuseppe","family":"Toffoli","sequence":"additional","affiliation":[{"name":"Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7517-7490","authenticated-orcid":false,"given":"Erika","family":"Cecchin","sequence":"additional","affiliation":[{"name":"Experimental and Clinical Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Demetri, G.D., Benjamin, R.S., Blanke, C.D., Blay, J.-Y., Casali, P., Choi, H., Corless, C.L., Debiec-Rychter, M., DeMatteo, R.P., and Ettinger, D.S. (2007). NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)--Update of the NCCN Clinical Practice Guidelines. J. Natl. Compr. Canc. Netw., 5.","DOI":"10.6004\/jnccn.2007.2002"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia","volume":"348","author":"Guilhot","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7510","DOI":"10.1158\/1078-0432.CCR-09-0190","article-title":"Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors","volume":"15","author":"Gramza","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/clpt.2013.208","article-title":"Interaction of the Efflux Transporters ABCB1 and ABCG2 With Imatinib, Nilotinib, and Dasatinib","volume":"95","author":"Eadie","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","article-title":"Functional Polymorphisms of the Human Multidrug-Resistance Gene: Multiple Sequence Variations and Correlation of One Allele with P-Glycoprotein Expression and Activity in Vivo","volume":"97","author":"Hoffmeyer","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.3892\/ol.2014.1857","article-title":"ABCB1 Haplotypes Are Associated with P-Gp Activity and Affect a Major Molecular Response in Chronic Myeloid Leukemia Patients Treated with a Standard Dose of Imatinib","volume":"7","author":"Vivona","year":"2014","journal-title":"Oncol. Lett."},{"key":"ref_8","first-page":"611","article-title":"C421A Polymorphism in the Human Breast Cancer Resistance Protein Gene Is Associated with Low Expression of Q141K Protein and Low-Level Drug Resistance","volume":"1","author":"Imai","year":"2002","journal-title":"Mol. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/jps.23436","article-title":"Interindividual Variability in the Hepatic Expression of the Human Breast Cancer Resistance Protein (BCRP\/ABCG2): Effect of Age, Sex, and Genotype","volume":"102","author":"Prasad","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2217\/pgs-2016-0124","article-title":"Pharmacogenetics of Drug Transporters in Modulating Imatinib Disposition and Treatment Outcomes in Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Patients","volume":"17","author":"Chen","year":"2016","journal-title":"Pharmacogenomics"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1124\/jpet.103.055574","article-title":"Interaction of Imatinib Mesilate with Human P-Glycoprotein","volume":"307","author":"Hamada","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","article-title":"Imatinib Mesylate (STI571) Is a Substrate for the Breast Cancer Resistance Protein (BCRP)\/ABCG2 Drug Pump","volume":"104","author":"Burger","year":"2004","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Dalle Fratte, C., Gagno, S., Roncato, R., Polesel, J., Zanchetta, M., Buzzo, M., Posocco, B., De Mattia, E., Borsatti, R., and Puglisi, F. (2022). CYP2D6 and CYP2C8 Pharmacogenetics and Pharmacological Interactions to Predict Imatinib Plasmatic Exposure in GIST Patients. Brit. J. Clin. Pharma, 1\u201310.","DOI":"10.1111\/bcp.15551"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"20640","DOI":"10.1038\/s41598-020-77140-9","article-title":"Plasma Imatinib Levels and ABCB1 Polymorphism Influences Early Molecular Response and Failure-Free Survival in Newly Diagnosed Chronic Phase CML Patients","volume":"10","author":"Rajamani","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/jcpt.12424","article-title":"Influence of CYP3A5*3 and ABCB1 C3435T on Clinical Outcomes and Trough Plasma Concentrations of Imatinib in Nigerians with Chronic Myeloid Leukaemia","volume":"41","author":"Adeagbo","year":"2016","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.5114\/aoms.2018.73538","article-title":"The Significance of Enzyme and Transporter Polymorphisms for Imatinib Plasma Levels and Achieving an Optimal Response in Chronic Myeloid Leukemia Patients","volume":"14","author":"Belohlavkova","year":"2018","journal-title":"Arch. Med. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00280-015-2905-6","article-title":"A Study to Explore the Correlation of ABCB1, ABCG2, OCT1 Genetic Polymorphisms and Trough Level Concentration with Imatinib Mesylate-Induced Thrombocytopenia in Chronic Myeloid Leukemia Patients","volume":"76","author":"Francis","year":"2015","journal-title":"Cancer. Chemother. Pharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.phrs.2017.03.011","article-title":"Influence of MDR1 and CYP3A5 Genetic Polymorphisms on Trough Levels and Therapeutic Response of Imatinib in Newly Diagnosed Patients with Chronic Myeloid Leukemia","volume":"120","author":"Harivenkatesh","year":"2017","journal-title":"Pharmacol. Res"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/annonc\/mds532","article-title":"Influence of Enzyme and Transporter Polymorphisms on Trough Imatinib Concentration and Clinical Response in Chronic Myeloid Leukemia Patients","volume":"24","author":"Seong","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.phrs.2018.02.005","article-title":"Impact of SLC22A1 and CYP3A5 Genotypes on Imatinib Response in Chronic Myeloid Leukemia: A Systematic Review and Meta-Analysis","volume":"131","author":"Cargnin","year":"2018","journal-title":"Pharmacol. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","article-title":"Multidrug Resistance Gene (MDR1) Polymorphisms Are Associated with Major Molecular Responses to Standard-Dose Imatinib in Chronic Myeloid Leukemia","volume":"112","author":"Dulucq","year":"2008","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/leu.2010.86","article-title":"HOCT1 Transcript Levels and Single Nucleotide Polymorphisms as Predictive Factors for Response to Imatinib in Chronic Myeloid Leukemia","volume":"24","author":"Bazeos","year":"2010","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00280-014-2630-6","article-title":"Association of ABCG2 Polymorphism with Clinical Efficacy of Imatinib in Patients with Gastrointestinal Stromal Tumor","volume":"75","author":"Koo","year":"2015","journal-title":"Cancer. Chemother. Pharm."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2008.20.4818","article-title":"Imatinib Plasma Levels Are Correlated with Clinical Benefit in Patients with Unresectable\/Metastatic Gastrointestinal Stromal Tumors","volume":"27","author":"Demetri","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough Imatinib Plasma Levels Are Associated with Both Cytogenetic and Molecular Responses to Standard-Dose Imatinib in Chronic Myeloid Leukemia","volume":"109","author":"Picard","year":"2006","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ctrv.2010.10.001","article-title":"Correlations between Imatinib Pharmacokinetics, Pharmacodynamics, Adherence, and Clinical Response in Advanced Metastatic Gastrointestinal Stromal Tumor (GIST): An Emerging Role for Drug Blood Level Testing?","volume":"37","author":"Widmer","year":"2011","journal-title":"Cancer Treat Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clpt.2006.05.003","article-title":"Association of Enzyme and Transporter Genotypes with the Pharmacokinetics of Imatinib","volume":"80","author":"Gardner","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00228-015-1901-4","article-title":"Effect of CYP3A5 and ABCB1 Polymorphisms on the Interaction between Tacrolimus and Itraconazole in Patients with Connective Tissue Disease","volume":"71","author":"Togashi","year":"2015","journal-title":"Eur. J. Clin. Pharm."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7102","DOI":"10.1158\/1078-0432.CCR-08-0950","article-title":"Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and Adults","volume":"14","author":"Petain","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"100441","DOI":"10.1016\/j.dmpk.2021.100441","article-title":"Impacts of SNPs on Adverse Events and Trough Concentration of Imatinib in Patients with Gastrointestinal Stromal Tumors","volume":"43","author":"Maekawa","year":"2022","journal-title":"Drug. Metab. Pharm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"29559","DOI":"10.1038\/srep29559","article-title":"Impact of ABCB1 1236C\u2009>\u2009T-2677G\u2009>\u2009T-3435C\u2009>\u2009T Polymorphisms on the Anti-Proliferative Activity of Imatinib, Nilotinib, Dasatinib and Ponatinib","volume":"6","author":"Dessilly","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/jth.13577","article-title":"Interindividual Variability in Dabigatran and Rivaroxaban Exposure: Contribution of ABCB1 Genetic Polymorphisms and Interaction with Clarithromycin","volume":"15","author":"Delavenne","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/FTD.0b013e3181b2c8cf","article-title":"A Therapeutic Drug Monitoring Algorithm for Refining the Imatinib Trough Level Obtained at Different Sampling Times","volume":"31","author":"Wang","year":"2009","journal-title":"Ther. Drug Monit."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological Index for Non-Randomized Studies (MINORS): Development and Validation of a New Instrument: Methodological Index for Non-Randomized Studies","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J. Surg."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/(SICI)1097-0258(19990215)18:3<321::AID-SIM28>3.0.CO;2-P","article-title":"Meta-Analysis: Formulating, Evaluating, Combining, and Reporting","volume":"18","author":"Normand","year":"1999","journal-title":"Stat. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/4\/3303\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:26:50Z","timestamp":1760120810000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/4\/3303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,7]]},"references-count":36,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["ijms24043303"],"URL":"https:\/\/doi.org\/10.3390\/ijms24043303","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,7]]}}}